CLDX Share Price

Open 3.29 Change Price %
High 3.33 1 Day 0.06 1.83
Low 3.22 1 Week -0.04 -1.19
Close 3.33 1 Month -0.25 -6.98
Volume 1281042 1 Year -0.20 -5.67
52 Week High 5.13
52 Week Low 2.85
CLDX Important Levels
Resistance 2 3.43
Resistance 1 3.39
Pivot 3.29
Support 1 3.27
Support 2 3.23
NASDAQ USA Most Active Stocks
MU 28.43 7.40%
MU 28.43 7.40%
MU 28.43 7.40%
FNFG 10.18 -0.20%
FTR 2.09 7.73%
FTR 2.09 7.73%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
AMCF 0.10 100.00%
VALV 0.04 100.00%
LOCM 0.09 50.00%
BGMD 0.08 33.33%
ESMC 0.12 33.33%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

CLDX Technical Analysis 3
As on 24th Mar 2017 CLDX Share Price closed @ 3.33 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.89 & Sell for SHORT-TERM with Stoploss of 3.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
CLDX Target for March
1st Target up-side 3.8
2nd Target up-side 3.98
3rd Target up-side 4.17
1st Target down-side 3.28
2nd Target down-side 3.1
3rd Target down-side 2.91
CLDX Other Details
Segment EQ
Market Capital 363793952.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celldextherapeutics.com
CLDX Address
CLDX
Perryville III Building
53 Frontage Road
Hampton, NJ 08827
United States
Phone: 908-200-7500
Fax: 908-454-1911
CLDX Latest News
Interactive Technical Analysis Chart Celldex Therapeutics, Inc. ( CLDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Celldex Therapeutics, Inc.
CLDX Business Profile
Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.